Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma release_rev_ac374e5c-eae1-4a50-b01b-a7c1d1a3d5e0

by Pauline Krämer, Aline Talhouk, Mary Anne Brett, Derek S Chiu, Evan S Cairns, Daniëlla A Scheunhage, Rory FL Hammond, David Farnell, Tayyebeh Mehrane Nazeran, Marcel Grube, Zhouchunyang Xia, Janine Senz (+29 others)

Published in Clinical Cancer Research by American Association for Cancer Research (AACR).

2020   clincanres.1268.2020

Abstract

Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared to other ovarian carcinomas. Nonetheless, current patient treatment continues to follow a "one-size-fits-all" approach. Even though tumor staging offers stratification, personalized treatments remain elusive. As ENOC shares many clinical and molecular features with its endometrial counterpart, we sought to investigate TCGA-inspired endometrial cancer (EC) molecular subtyping in a cohort of ENOC. Immunohistochemistry and mutation biomarkers were used to segregate 511 ENOC tumors into four EC-inspired molecular subtypes: low-risk POLE mutant (POLEmut); moderate-risk mismatch repair deficient (MMRd); high-risk p53 abnormal (p53abn); moderate-risk with no specific molecular profile (NSMP). Survival analysis with established clinicopathological and subtypes specific features was performed. 3.5% of cases were POLEmut, 13.7% MMRd, 9.6% p53abn and 73.2% NSMP, each showing distinct outcomes (p <0.001) and survival similar to observations in EC. Median OS was 18.1 years in NSMP, 12.3 years in MMRd; 4.7 years in p53abn and not reached for POLEmut cases. Subtypes were independent of stage, grade, and residual disease in multivariable analysis. EC-inspired molecular classification provides independent prognostic information in ENOC. Our findings support investigating molecular-subtype specific management recommendations for ENOC patients; for example, subtypes may provide guidance when fertility-sparing treatment is desired. Similarities between ENOC and EC suggest that ENOC patients may benefit from management strategies applied to EC and the opportunity to study those in umbrella trials.
In text/plain format

Type  article-journal
Stage   published
Date   2020-07-31
Language   en ?
Container Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  1078-0432
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Revision

This is a specific, static metadata record, not necessarily linked to any current entity in the catalog.

Catalog Record
Revision: ac374e5c-eae1-4a50-b01b-a7c1d1a3d5e0
API URL: JSON